Literature DB >> 15713996

S100A4 expression is an early event of papillary carcinoma of the thyroid.

Yasuhiro Ito1, Hiroshi Yoshida, Chisato Tomoda, Takashi Uruno, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Kennichi Kakudo, Kanji Kuma, Akira Miyauchi.   

Abstract

OBJECTIVES: S100A4 is a calcium-binding protein related to the metastatic potential of carcinoma. In order to elucidate its contribution to the progression of thyroid carcinoma, we investigated S100A4 expression in various thyroid neoplasms.
METHODS: We immunohistochemically examined S100A4 expression in 195 cases of thyroid neoplasms.
RESULTS: Although S100A4 was absent in normal follicular cells and follicular adenoma, S100A4 was positive in all 115 cases of papillary carcinoma examined, including 58 microcarcinomas. However, a significant relationship could not be established between S100A4 expression and clinicopathological features of papillary carcinoma. In follicular carcinoma, the widely invasive type expressed S100A4 more frequently than the minimally invasive type (p = 0.0028). In anaplastic carcinoma, S100A4 was expressed in 61.9% of cases, but the incidence was significantly lower (p < 0.0001) than that in papillary carcinoma.
CONCLUSIONS: These findings suggest that (1) S100A4 plays a constitutive role in papillary carcinoma and (2) S100A4 may be a useful marker for early the detection of this carcinoma. Copyright (c) 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15713996     DOI: 10.1159/000082924

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  11 in total

1.  Mts1 Up-regulation is Associated With Aggressive Pathological Features in Thyroid Cancer.

Authors:  Min Gyeong Cheon; Ye Won Son; Joon-Hyop Lee; Ho Hee Jang; Yoo Seung Chung
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

2.  Stable knockdown of S100A4 suppresses cell migration and metastasis of osteosarcoma.

Authors:  Masahiko Fujiwara; Takeshi G Kashima; Akiko Kunita; Isao Kii; Daisuke Komura; Agamemnon E Grigoriadis; Akira Kudo; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Tumour Biol       Date:  2011-03-01

3.  Proteomics Profiling of the Urine of Patients with Hyperthyroidism after Anti-Thyroid Treatment.

Authors:  Hicham Benabdelkamel; Afshan Masood; Aishah A Ekhzaimy; Assim A Alfadda
Journal:  Molecules       Date:  2021-04-01       Impact factor: 4.411

4.  Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Authors:  Nobuki Nakamura; Lori A Erickson; Long Jin; Sabine Kajita; Heyu Zhang; Xiang Qian; Kandelaria Rumilla; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

5.  Overexpression of S100A4 in human cancer cell lines resistant to methotrexate.

Authors:  Nuria Mencía; Elisabet Selga; Isabel Rico; M Cristina de Almagro; Xenia Villalobos; Sara Ramirez; Jaume Adan; Jose L Hernández; Véronique Noé; Carlos J Ciudad
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

6.  A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours.

Authors:  Juan Martínez-Aguilar; Roderick Clifton-Bligh; Mark P Molloy
Journal:  BMC Cancer       Date:  2015-03-29       Impact factor: 4.430

7.  Increased expression levels of S100A4 associated with hypoxia-induced invasion and metastasis in esophageal squamous cell cancer.

Authors:  Xiaoyan Xuan; Qianru Li; Zhongning Zhang; Ying Du; Pingping Liu
Journal:  Tumour Biol       Date:  2014-09-13

8.  Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.

Authors:  Hye Sook Min; Chul Lee; Kyeong Cheon Jung
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

9.  Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery.

Authors:  Chia-Chun Wu; Jen-Der Lin; Jeng-Ting Chen; Chih-Min Chang; Hsiao-Fen Weng; Chuen Hsueh; Hui-Ping Chien; Jau-Song Yu
Journal:  Oncotarget       Date:  2018-01-04

10.  S100A12 is a promising biomarker in papillary thyroid cancer.

Authors:  Xiaojie Wang; Zhenxiang Sun; Wei Tian; Chenghao Piao; Xiaochen Xie; Jin Zang; Shiqiao Peng; Xiaohui Yu; Yiwei Wang
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.